TENAYA THERAPEUTICS TNYA 深 沪
等待开盘 08-13 09:30:00 美东时间
0.757
+0.076
+11.13%
华盛通- 最 高0.759
- 今 开0.68
- 成交量 248.69万股
- 最 低 0.67
- 昨 收 0.6812
- 总市值 1.23亿
- 52周最高 4.01
- 市盈率 静 --
- 换手率 1.53%
- 52周最低 0.36
- 委 比 -82.99%
- 总股本 1.63亿
- 历史最高 32.00
- 量 比 1.84
- 振 幅 13.07%
- 历史最低 0.36
- 每 手 1
- 风险率 1.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Tenaya Therapeutics' CEO, Faraz Ali, will speak at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The event will be webcast live and available via the Investors section of Tenaya's website, with an archive for 30 days. Tenaya focuses on developing curative therapies for heart diseases, with clinical-stage candidates TN-201 and TN-401 targeting genetic cardiomyopathies. The company leverages genetic insights and innovative...
08-08 12:00
Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.
08-07 20:50
Tenaya Therapeutics Q2 EPS $(0.14) Beats $(0.17) Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.17) by 17.65 percent. This is a 58.82 percent increase over losses of $(0.34) per share
08-07 05:13
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Tenaya Therapeutics announced the completion of enrollment and positive safety reviews for its gene therapy trials for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The Data Safety Monitoring Board recommended dose escalation and expansion for both TN-201 and TN-401 trials, with initial data expected in the fourth quarter of 2025. The company reported a cash runway ...
08-06 20:30
Tenaya Therapeutics Completes Enrollment In MyPEAK-1 Trial For HCM And Initiates RIDGE-1 Trial For ARVC With DSMB Endorsements
Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected
07-30 20:36
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed
Tenaya Therapeutics announced positive endorsements from independent Data Safety and Monitoring Boards (DSMBs) for its MyPEAK-1 (TN-201) and RIDGE-1 (TN-401) gene therapy clinical trials targeting hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC), respectively. Both trials were granted approval to proceed as planned. Initial data from Cohort 1 of MyPEAK-1 showed promising results, including improved card...
07-30 12:30
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.
05-09 18:53
Tenaya Therapeutics GAAP EPS of -$0.24
Tenaya Therapeutics press release (NASDAQ:TNYA): Q1 GAAP EPS of -$0.24. As of March 31, 2025, cash, cash equivalents and investments in marketable securities were $88.2 million. More on Tenaya Thera...
05-08 05:44
Tenaya Therapeutics Q1 EPS $(0.24) Misses $(0.20) Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.20) by 20 percent. This is a 40 percent increase over losses of $(0.40) per share from
05-08 05:26
